UPJOHN, ROBINS AND SCHERING WIN BACK SOME LOST GROUND; INDEX FALTERS
Executive Summary
Rebounding Upjohn (up 2-5/8 to 115-3/4), Robins (up 2 to 12-1/8) and Schering (up 1-3/4to 49-3/4) were the leaders on the "F-D-C" Index as drug/diversified stocks continued to head south during the week ended August 2. The three drug firms had been among several big losers the previous week. Robins had lost 8-1/4 points after the company suggested that Chapter 11 might be an answer to its Dalkon Shield litigation problems. Upjohn had fallen 5-3/4 the week ending July 26 after slipping several points the previous week, while Schering had slid 4-1/8. Chart omitted.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth